AG
BMY icon

Ascent Group’s Bristol-Myers Squibb BMY Stock Holding History

Ascent Group’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.31M Buy
38,067
+17,492
+85% +$1.02M 0.08% 228
2025
Q4 		$1.11M Buy
20,575
+4,919
+31% +$237K 0.04% 346
2025
Q3 		$706K Sell
15,656
-37,850
-71% -$1.77M 0.03% 429
2025
Q2 		$2.48M Buy
53,506
+316
+0.6% +$15.5K 0.1% 195
2025
Q1 		$3.24M Buy
53,190
+8,721
+20% +$508K 0.14% 163
2024
Q4 		$2.52M Buy
44,469
+12,227
+38% +$683K 0.19% 139
2024
Q3 		$1.67M Buy
+32,242
New +$1.51M 0.13% 212
2023
Q2 		– Sell
-7,075
Closed -$490K – 456
2023
Q1 		$490K Sell
7,075
-4,065
-36% -$287K 0.05% 322
2022
Q4 		$801K Sell
11,140
-5,352
-32% -$404K 0.09% 240
2022
Q3 		$1.28M Buy
16,492
+4,148
+34% +$301K 0.16% 180
2022
Q2 		$911K Buy
12,344
+243
+2% +$18.5K 0.11% 219
2022
Q1 		$884K Buy
12,101
+2,996
+33% +$201K 0.1% 232
2021
Q4 		$579K Buy
+9,105
New +$534K 0.07% 277

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ascent Group's BMY Position: Q1 2026 in Review

Ascent Group increased its Bristol-Myers Squibb (BMY) stake by 85% in Q1 2026, buying an estimated $1.02M and bringing the position to 38,067 shares worth $2.31M. The position accounts for 0.08% of the portfolio, ranked #228.

Ascent Group first reported a position in BMY in Q4 2021 and has held it in 13 quarters since. The position peaked at $3.24M in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Ascent Group held 38,067 shares of Bristol-Myers Squibb worth $2.31M as of Q1 2026.
  • Ascent Group bought 17,492 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.02M.
  • Bristol-Myers Squibb made up 0.08% of Ascent Group's portfolio in Q1 2026, its #228 holding.
  • Ascent Group first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 13 quarters since.
  • Ascent Group's Bristol-Myers Squibb position peaked at $3.24M in Q1 2025.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Ascent Group's 13F filing for Q1 2026, filed 15 May 2026.